Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California.
IPO Year:
Exchange: NASDAQ
Website: simulations-plus.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/15/2024 | $39.00 | Overweight | Stephens |
| 7/29/2024 | $47.00 | Overweight | KeyBanc Capital Markets |
| 7/16/2024 | Mkt Perform | JMP Securities | |
| 6/28/2024 | Outperform | William Blair | |
| 5/9/2023 | $55.00 | Buy | BTIG Research |
| 10/26/2021 | $65.00 → $53.00 | Hold → Buy | Craig Hallum |
| 7/13/2021 | $95.00 → $54.00 | Outperform | Raymond James |
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus", "SLP"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it will participate in two healthcare investor conferences in February. The Company is attending the BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference taking place in Snowbird, Utah. Shawn O'Connor, Chief Executive Officer, will host one-on-one meetings with institutional investors on Tuesday, February 11, 2025. The Company is also attending the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Industry partners to provide funding and data to support ACAT™ model improvements Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at advancing in vitro-in vivo correlation (IVIVC) approaches for oral drug delivery and expanding the functionality of the GastroPlus platform. The collaboration focuses on enhancing the predictive capabilities of the GastroPlus advanced compartmental absorption and
SLP's technology and expertise accelerates drug development and supports critical advancements in global healthcare Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today highlighted its impact on the pharmaceutical industry through supporting the development of 100% of the drugs approved by the U.S. Food and Drug Administration (FDA) in 2024. "For more than 25 years, our clients have entrusted us to provide the mission-critical software and services needed to develop therapies that are changing the landscape of h
Total revenue up 31% year-over-year primarily driven by strong software growth Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its first quarter fiscal 2025, ended November 30, 2024. First Quarter 2025 Financial Highlights (compared to first quarter 2024) Total revenue increased 31% to $18.9 million Software revenue increased 41% to $10.7 million, representing 57% of total revenue Services revenue increased 19% to $8.2 million, representing 43% of total revenue Gro
Conference call to be on Tuesday, January 7, 2025, at 5 p.m. ET Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that it will report first quarter fiscal 2025 financial results after the market close on Tuesday, January 7, 2025. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-4
Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O'Connor, chief executive officer, will participate in the virtual BTIG Digital Health Forum on Monday, November 25, 2024. Mr. O'Connor will join a panel discussion entitled "Supporting Drug Development, Clinical Trials, and Biopharma" at 2:00 p.m. Eastern Time. In addition, Mr. O'Connor will host one-on-one meetings throughout the day. For more information about the BTIG Digital Health Forum, or to register to attend, please visit the BTIG website. For mor
Funded collaboration will leverage current FDA partnership to include additional LAI technologies Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has been awarded a newly funded grant from the U.S. Food and Drug Administration (FDA) to use physiologically based pharmacokinetic (PBPK) approaches in GastroPlus® to build and validate mechanistic in vitro-in vivo correlations (IVIVCs) for long-acting injectable (LAI) technologies through a joint proposal with the University of Connecticut's School of Pharmacy, D
Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O'Connor, chief executive officer, will participate in a fireside chat at the Stephens Annual Investment Conference in Nashville, TN, on Wednesday, November 20, 2024, at 12:00 p.m. Eastern Time. In addition, Mr. O'Connor will host one-on-one meetings with investors throughout the day. The live audio webcast of Mr. O'Connor's fireside chat can be accessed via this link and also on the Investors page of the Simulations Plus website where the replay will be avai
Collaboration goal to develop alternative methods to assess clinical performance of product variants under different conditions Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced a newly funded grant from the U.S. Food and Drug Administration (FDA), secured in partnership with the University of Strathclyde and InnoGI Technologies. The project is expected to improve the understanding of amorphous solid dispersion (ASD) formulations in different conditions and predict the impact of food and pH-dependent drug-drug interact
Fiscal 2024 revenue grew 18% year-over-year to $70 million, with diluted earnings per share (EPS) of $0.49 Provides fiscal 2025 revenue guidance of $90 to $93 million (+28% to +33%) and adjusted diluted EPS guidance of $1.07 to $1.20 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its fourth quarter and fiscal 2024, ended August 31, 2024. Fourth Quarter 2024 Financial Highlights (compared to fourth quarter 2023) Total revenue increased 19% to $18.7 million Software revenue increased 6% to $
QHP Capital, L.P. ("QHP"), an investor in technology and services companies in the life sciences and healthcare sectors, today announced its sale of Pro-ficiency, LLC ("Pro-ficiency" or the "Company"), a leader in providing tech-enabled training and compliance solutions for clinical trial investigators and site staff, to Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy. Michael Raymer, Chief Executive Officer of Pro-ficiency, said, "We are excited to join the Simulations Plus team, which has a well-established and recognized leadership position in modeling and simulations wi
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), announced today the appointment of Will Frederick as chief financial officer (CFO), succeeding John Kneisel, who retires after seven years with the company. Will Frederick brings more than 25 years of financial leadership experience to the company. He has a proven track record of developing and implementing strategies to drive revenue growth, increase profitability, managing merger & acquisition activities and achieving corporate objectives. He has global experience with both publicly traded and privately held companies including Pharsight, Entelos, Avaya, The Walt Disney Company and Ford Motor Company, among
8-K - Simulations Plus, Inc. (0001023459) (Filer)
10-Q - Simulations Plus, Inc. (0001023459) (Filer)
8-K - Simulations Plus, Inc. (0001023459) (Filer)
DEFA14A - Simulations Plus, Inc. (0001023459) (Filer)
DEF 14A - Simulations Plus, Inc. (0001023459) (Filer)
10-K - Simulations Plus, Inc. (0001023459) (Filer)
8-K - Simulations Plus, Inc. (0001023459) (Filer)
8-K - Simulations Plus, Inc. (0001023459) (Filer)
10-Q - Simulations Plus, Inc. (0001023459) (Filer)
8-K - Simulations Plus, Inc. (0001023459) (Filer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
Total revenue up 31% year-over-year primarily driven by strong software growth Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its first quarter fiscal 2025, ended November 30, 2024. First Quarter 2025 Financial Highlights (compared to first quarter 2024) Total revenue increased 31% to $18.9 million Software revenue increased 41% to $10.7 million, representing 57% of total revenue Services revenue increased 19% to $8.2 million, representing 43% of total revenue Gro
Conference call to be on Tuesday, January 7, 2025, at 5 p.m. ET Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that it will report first quarter fiscal 2025 financial results after the market close on Tuesday, January 7, 2025. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-4
Fiscal 2024 revenue grew 18% year-over-year to $70 million, with diluted earnings per share (EPS) of $0.49 Provides fiscal 2025 revenue guidance of $90 to $93 million (+28% to +33%) and adjusted diluted EPS guidance of $1.07 to $1.20 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its fourth quarter and fiscal 2024, ended August 31, 2024. Fourth Quarter 2024 Financial Highlights (compared to fourth quarter 2023) Total revenue increased 19% to $18.7 million Software revenue increased 6% to $
Conference call to be on Wednesday, October 23, 2024, at 5 p.m. EDT Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), announced today that it will report fourth quarter and fiscal 2024 financial results after the market close on Wednesday, October 23, 2024. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this Call me™ link to request a return call. The webcast can be access
Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today reported financial results for its third quarter fiscal 2024, ended May 31, 2024. Third Quarter 2024 Financial Highlights (compared to third quarter 2023) Total revenue increased 14% to $18.5 million Software revenue increased 12% to $11.9 million, representing 64% of total revenue Services revenue increase
Conference call to be on Tuesday, July 2, 2024, at 5 p.m. EDT Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), announced today that it will report third quarter fiscal 2024 financial results after the market close on Tuesday, July 2, 2024. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this Call me™ link to request a return call. The webcast can be accessed on the inves
Total revenue of $18.3 million and diluted earnings per share (EPS) of $0.20 Maintains full-year revenue guidance of $66 to $69 million (+10-15%) and EPS guidance of $0.66 to $0.68 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second quarter fiscal 2024, ended February 29, 2024. Second Quarter 2024 Financial Highlights (compared to second quarter 2023) Total revenue increased 16% to $18.3 million Software revenue increased 11% to $11.6 million, representing 63% of total revenue Services revenue increased 27% to $6.7 m
Conference call to be on Wednesday, April 3, 2024, at 5 p.m. EDT Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), announced today that it will report second quarter fiscal 2024 financial results after the market close on Wednesday, April 3, 2024. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this Call me™ link to request a return call. The webcast can be accessed on th
Total revenue of $14.5 million and diluted earnings per share (EPS) of $0.10 Maintains full-year revenue guidance of $66 to $69 million (+10-15%) and EPS guidance of $0.66 to $0.68 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its first quarter fiscal 2024, ended November 30, 2023. First Quarter Financial Highlights Total revenue increased 21% to $14.5 million Software revenue increased 25% to $7.6 million, representing 52% of total revenue Services revenue increased 17% to $6.9 million, representing 48% of total revenue
Conference call to be on Wednesday, January 3, 2024, at 5 p.m. EST Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), announced today that it will report first quarter fiscal 2024 financial results after the market close on Wednesday, January 3, 2024. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this Call me™ link to request a return call. The webcast can be accessed on
Stephens initiated coverage of Simulations Plus with a rating of Overweight and set a new price target of $39.00
KeyBanc Capital Markets initiated coverage of Simulations Plus with a rating of Overweight and set a new price target of $47.00
JMP Securities initiated coverage of Simulations Plus with a rating of Mkt Perform
William Blair initiated coverage of Simulations Plus with a rating of Outperform
BTIG Research initiated coverage of Simulations Plus with a rating of Buy and set a new price target of $55.00
Craig Hallum upgraded Simulations Plus from Hold to Buy and set a new price target of $53.00 from $65.00 previously
Raymond James reiterated coverage of Simulations Plus with a rating of Outperform and set a new price target of $54.00 from $95.00 previously